Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
about
Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyCost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States.Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives.
P2860
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Lifetime cost of everolimus vs ...... r sunitinib therapy in the US.
@ast
Lifetime cost of everolimus vs ...... r sunitinib therapy in the US.
@en
type
label
Lifetime cost of everolimus vs ...... r sunitinib therapy in the US.
@ast
Lifetime cost of everolimus vs ...... r sunitinib therapy in the US.
@en
prefLabel
Lifetime cost of everolimus vs ...... r sunitinib therapy in the US.
@ast
Lifetime cost of everolimus vs ...... r sunitinib therapy in the US.
@en
P2093
P1476
Lifetime cost of everolimus vs ...... or sunitinib therapy in the US
@en
P2093
Allison Perrin
Andrew Chua
Kenneth Culver
Louis P Garrison
Magdaliz Gorritz
Steven Sherman
Sumanta Pal
Xufang Wang
Zhimei Liu
P304
P356
10.3111/13696998.2014.985789
P407
P577
2014-11-26T00:00:00Z